NCT07623174 A Study of Fruquintinib in Adults With Metastatic Colorectal Cancer in Poland
| NCT ID | NCT07623174 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Takeda |
| Condition | Metastatic Colorectal Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 110 participants |
| Start Date | 2026-08-13 |
| Primary Completion | 2028-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 110 participants in total. It began in 2026-08-13 with a primary completion date of 2028-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Metastatic colorectal cancer or mCRC is a cancer that starts in the parts of the large intestine (the colon or rectum) and has already spread to other parts of the body. This cancer can be hard to treat because it can behave differently from one person to another. Over time, treatments may stop working, and side effects can build up. In later treatment stages, there are only a few standard medicine options available. Because of this, studies often look at both how long people live and how treatment affects quality of life. The main aim of this study is to see how long adults in Poland with mCRC live without their cancer getting worse (progression-free survival or PFS) when they receive fruquintinib after at least two previous treatments. Fruquintinib (TAK 113) is a medicine taken by mouth that is designed to slow tumor growth. Other aim is to find out how long adults in Poland with mCRC live while being treated with fruquintinib (overall survival or OS). The study also wants to record how fruquintinib is used in routine care in adults with mCRC in Poland (for example when treatment starts, changes in doses, and how long treatment continues). Another aim is to learn about people with mCRC, such as their medical history and past treatment as well as their quality of life while they are in the study. The study will look at data already existing in the participants' medical charts.
Eligibility Criteria
Inclusion Criteria: 1. Adult participants (aged 18 years and older) with mCRC who are eligible for treatment with fruquintinib under the national drug program B.4 and will receive fruquintinib as third or subsequent line treatment after progression on or intolerance to trifluride/tipiracil. 2. Participants who signed informed consent to participate in the study at the time of enrollment and prior to the fruquintinib treatment initiation. 3. Participants for whom adequate medical records are available to support the data collection requirements. Exclusion Criteria: 1\. Participant currently participates or plans to participate in an interventional clinical trial.
Contact & Investigator
Study Director
STUDY DIRECTOR
Takeda
Frequently Asked Questions
Who can join the NCT07623174 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Metastatic Colorectal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07623174 currently recruiting?
Yes, NCT07623174 is actively recruiting participants. Contact the research team at medinfoUS@takeda.com for enrollment information.
Where is the NCT07623174 trial being conducted?
This trial is being conducted at Poznan, Poland, Bydgoszcz, Poland, Krakow, Poland, Lublin, Poland and 6 additional locations.
Who is sponsoring the NCT07623174 clinical trial?
NCT07623174 is sponsored by Takeda. The principal investigator is Study Director at Takeda. The trial plans to enroll 110 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.